(Alliance News) - Shares in Proteome Sciences PLC rose on Monday as the company appointed Mariola Sohngen as chief executive officer with effect on Tuesday.
Sohngen will be replacing Ian Pike, who was CEO on an interim basis since Jeremy Haigh stepped down at the end of 2019. Pike will return to the role of chief scientific officer.
Shares in the drug development services provider were 17% higher at 3.79 pence on Monday in London.
Sohngen's most recent activity was running pharmaceutical consultancy Dres Sohngen Beteiligungs GmbH since the start of 2020, focused on supporting Chinese companies in entering the European pharmaceutical market.
Prior to that, she was chief executive officer for Belgium-based drug development firm Convert Pharmaceuticals SA for a year from 2018 to 2019.
Before this, she was CEO at German biopharmaceutical firm Mologen AG for three years from 2015 to 2018, and prior to this was chief medical officer at German pharmaceutical Paion AG for 15 years from 2000 to 2015.
"The board is delighted to appoint Mariola Sohngen as our new CEO where she will build on the strong foundations that have already been established. Mariola's time as chief medical officer at Paion together with her international experience and network will bring major benefits to our business as we look to engage more broadly with new and existing clients in the US, Europe and to address the rapidly growing Asian markets," said Chair Christopher Pearce.
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Proteome (PRM)